EL20, A Potent Antiarrhythmic Compound, Selectively Inhibits Calmodulin-Deficient Ryanodine Receptor Type 2

Authors

Robert Klipp, Portland State University
Na Li, Baylor College of Medicine
Qiongling Wang, Baylor College of Medicine
Tarah A. Word, Baylor College of MedicineFollow
Martha Sibrian-Vazquez, Portland State UniversityFollow
Robert M. Strongin, Portland State UniversityFollow
Xander H.T. Wehrens, Baylor College of Medicine
Jonathan Abramson, Portland State University

Published In

Heart Rhythm

Document Type

Citation

Publication Date

4-1-2018

Abstract

This work provides a potential therapeutic mechanism for the development of antiarrhythmic compounds that inhibit leaky RyR2 resulting from CaM dissociation, which is often associated with failing hearts. Our data also suggest that CaM dissociation may contribute to the pathogenesis of arrhythmias with the CPVT-linked R176Q mutation.

Locate the Document

http://dx.doi.org/10.1016/j.hrthm.2017.12.017

DOI

10.1016/j.hrthm.2017.12.017

Persistent Identifier

https://archives.pdx.edu/ds/psu/25880

Citation Details

Klipp, R. C., Li, N., Wang, Q., Word, T. A., Sibrian-Vazquez, M., Strongin, R. M., ... & Abramson, J. J. (2017). EL20, A Potent Antiarrhythmic Compound, Selectively Inhibits Calmodulin Deficient Ryanodine Receptor Type 2. Heart rhythm, 15(4):578-586.